Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs -March 11, 2024 at 07:31 am EDT

Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior...

Related Keywords

San Diego ,California ,United States ,Michelle Greenman ,Racheln Grisham ,Dan Paterson ,Charlottec Sun ,Susanna Banerjee ,Exchange Commission ,Drug Administration ,Patient Impact ,Genfleet Therapeutics Shanghai Inc ,Linkedin ,Raf And Mek Program ,Chugai Pharmaceutical Co Ltd ,Society Of Gynecologic Oncology ,Secura Bio Inc ,Company Annual Report On Form ,Amgen ,Verastem Oncology ,Gynecologic Oncology ,Impact Survey ,Data Presentations ,Scientific Plenary ,Late Breaking Abstract Session ,Rare Cancer ,Uncommon Cancers ,Poster Session ,Progress Poster ,Breakthrough Therapy ,Orphan Drug Designation ,Secura Bio ,Genfleet Therapeutics ,Annual Report ,